Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Operating Income (2023 - 2025)

Historic Operating Income for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$60.1 million.

  • Immunome's Operating Income fell 1903.33% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 2622.53%. This contributed to the annual value of -$305.8 million for FY2024, which is 17919.29% down from last year.
  • As of Q3 2025, Immunome's Operating Income stood at -$60.1 million, which was down 1903.33% from -$46.5 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Operating Income ranged from a high of -$4.5 million in Q1 2023 and a low of -$132.3 million during Q1 2024
  • Over the past 3 years, Immunome's median Operating Income value was -$46.5 million (recorded in 2025), while the average stood at -$51.5 million.
  • As far as peak fluctuations go, Immunome's Operating Income plummeted by 285904.72% in 2024, and later surged by 6626.13% in 2025.
  • Over the past 3 years, Immunome's Operating Income (Quarter) stood at -$94.7 million in 2023, then increased by 12.34% to -$83.0 million in 2024, then increased by 27.52% to -$60.1 million in 2025.
  • Its Operating Income stands at -$60.1 million for Q3 2025, versus -$46.5 million for Q2 2025 and -$44.6 million for Q1 2025.